## References

### Chapter 5: Endocrinology

1. Simpson RW, Shaw JE, Zimmet PZ. The prevention of type 2 diabetes—lifestyle change or pharmacotherapy? A challenge for the 21st century. Diabetes Res Clin Pract 2003; 59(3):165-80. http://www.ncbi.nlm.nih.gov/m/pubmed/12590013/

2. Cartwright RD. The role of sleep in changing our minds: a psychologist's discussion of papers on memory reactivation and consolidation in sleep. Learn Mem 2004; 11(6):660-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC534693/

3. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 2003; 148(1):1-9. http://www.eje-online.org/content/148/1/1.long

4. Gale E. Is there really an epidemic of type 2 diabetes? Lancet 2003; 362:503-4. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14148-7/abstract

5. Inoue K, Matsumoto M, Akimoto K. Fasting plasma glucose and HbA1c as risk factors for type 2 diabetes. Diabet Med 2008; 25(10):1157-63. http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2008.02572.x/abstract

6. Westman EC, Yancy WS Jr, Mavropoulos JC, et al. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond) 2008; 5:36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633336/

7. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343:d6898. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223424/

8. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22):2117-28. http://www.nejm.org/doi/full/10.1056/NEJMc1600827

9. Dose Adjustment For Normal Eating (DAFNE). http://www.dafne.uk.com/

10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14):977-86. http://www.nejm.org/doi/full/10.1056/NEJM199309303291401

11. Belch J. Aspirin does not help as primary prevention in DM. BMJ 2008; 337:a1840. http://www.bmj.com/cgi/content/full/337/oct16_2/a1840

12. Davidson MB, Wong A, Hamrahian AH, et al. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract 2008; 14(8):985-92. http://journals.aace.com/doi/abs/10.4158/EP.14.8.985

13. NICE. Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care [CG73]. https://www.nice.org.uk/guidance/cg73

14. Murad MH, Coto-Yglesias F, Wang AT, et al. Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94(3):741-5. http://press.endocrine.org/doi/pdf/10.1210/jc.2008-1416

15. Kapoor RR, James C, et al. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. Nat Clin Pract Endocrinol Metab 2009; 5(2):101-12. http://www.nature.com/nrendo/journal/v5/n2/full/ncpendmet1046.html

16. Geraghty M, Draman M, Moran D, et al. Hypoglycaemia in an adult male: a surprising finding in pursuit of insulinoma. Surgeon 2008; 6(1):57-60

17. Abraham P, Avenell A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005; 153(4):489-98. http://www.eje-online.org/content/153/4/489.long

18. Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005; 90(9):5234-40. http://press.endocrine.org/doi/pdf/10.1210/jc.2005-0148

19. Hedback G, Odén A. Recurrence of hyperparathyroidism; a long-term follow-up after surgery for primary hyperparathyroidism. Eur J Endocrinol 2003; 148(4):413-21. http://www.eje-online.org/content/148/4/413.long

20. Hoff AO, Cote GJ, Gagel RF. Multiple endocrine neoplasias. Annu Rev Physiol 2000; 62:377. http://www.annualreviews.org/doi/pdf/10.1146/annurev.physiol.62.1.377

21. Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab 2008; 22(4):639-57. http://pubmedhh.nlm.nih.gov/cgi-bin/abstract.cgi?id=18971124&from=cqsr

22. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol 1994; 40:479-84. http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.1994.tb02486.x/abstract

23. Brosnan CM, Gowing NF. Addison's disease. BMJ 1996; 312(7038):1085-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350885/

24. State Coroner for Western Australia. Failure to diagnose: Addison's disease. 2007. http://www.racgp.org.au/afp/200710/200710bird.pdf

25. Boyle JG, Davidson DF, Perry CG, et al. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 2007; 92(12):4602-8. http://press.endocrine.org/doi/pdf/10.1210/jc.2005-2668

26. Herrmann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342(22):1622-6. http://www.nejm.org/doi/full/10.1056/NEJM200006013422201

27. Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord 2009; 10(2):135-44. http://link.springer.com/article/10.1007%2Fs11154-008-9106-0

28. Chanson P. Acromegaly. Presse Med 2009; 38(1):92-102. https://www.ncbi.nlm.nih.gov/pubmed/19004612

### Chapter 6: Gastroenterology

1. Al Moutran H. Microstomia. Medscape. 2015. http://www.emedicine.com/ent/topic148.htm

2. Batur P, Stewart WJ, Isaacson JH. Increased prevalence of aortic stenosis in patients with arteriovenous malformations of the gastrointestinal tract in Heyde syndrome. Arch Intern Med 2003; 163(15):1821-4. http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/755859

3. Unlugenc H, Guler T, Gunes Y, Isik G. Comparative study of the antiemetic efficacy of ondansetron, propofol and midazolam in the early postoperative period. Eur J Anaesthesiol 2004; 21(1):60-5. http://pubmedhh.nlm.nih.gov/cgi-bin/abstract.cgi?id=14768925&from=cqsr